Clinical Trials Browser

Not yet recruiting × Paclitaxel × Breast × Clear all

NCT07441486 2026-03-02

A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07300475 2026-02-13

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07396324 2026-02-09

NEO-ITHRAN

Phase 2 Not yet recruiting

Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

NCT07283692 2026-02-03

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Phase 1 Not yet recruiting

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07187674 2025-09-23

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Phase NA Not yet recruiting

Triple Negative Breast Neoplasms

NCT06407310 2024-05-09

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06371807 2024-04-17

KEYPARTNER

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06297811 2024-03-07

Myeloprotection With Trilaciclib in Pan-cancer Population

Phase 2 Not yet recruiting

BreastGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT05841381 2023-05-03

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

Phase 3 Not yet recruiting

Breast Neoplasms

NCT05388500 2022-05-27

PHARE-C

Phase 3 Not yet recruiting

HER2-positive Breast Cancer

NCT05287308 2022-03-31

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

Phase NA Not yet recruiting

Breast Neoplasms

NCT05131893 2021-11-23

Neoadjuvant Treatment of Breast Cancer

Not yet recruiting

Breast Neoplasms

NCT05067530 2021-10-05

CAREGIVER

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT04301375 2020-03-10

ELPIS

Phase 2 Not yet recruiting

Breast Neoplasms